Date: 2012-01-26
Type of information:
Compound: coagulation assays
Company: Roche (Switerland) Technoclone (Austria)
Therapeutic area: Cardiovascular diseases - Hematological diseases
Type agreement: R&D
co-development
Action mechanism:
Disease:
Details: Roche has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, to co-develop a complete range of coagulation assays. The alliance supports plans Roche announced in October 2011 to develop a new line of analyzers for the central coagulation lab, which will be marketed under Roche's cobas® brand. The new line is expected to be introduced in the U.S. and Canada in 2014, subject to regulatory approval and other requirements. As part of the alliance, Roche will also market Technoclone's range of Research Use Only products that address the needs of specialists and researchers in the hemostasis research community. The agreement follows Roche's announcement in December 2011 that it was acquiring Verum Diagnostica GmbH, a leading company in platelet function testing, the fastest-growing field in the coagulation diagnostics market (See http://biopharmanalyses.fr/merges-and-acquisitions/?pageid=68).
Financial terms:
Latest news:
